MedTrace Logo

Medication Review Focusing on Anticoagulation Therapy in Swiss Community Pharmacies

NCT02703727 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 90

Last updated 2016-12-08

No results posted yet for this study

Summary

Oral anticoagulation therapy (OAC) entails a high potential for adverse events and strict adherence is needed.Thus, medication review and identification of safety issues and knowledge gaps about OAC is critically important. The polymedication check (PMC) is a reimbursed intermediate medication review focusing on adherence and medication management for Swiss primary care. Investigators aime to assess the impact of the PMC extended with a semi-structured interview focusing on OAC.

Conditions

  • Drug Therapy Management

Interventions

BEHAVIORAL

Extended polymedication check

Behavioral: Medication review Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n\>3 drugs) on long term conditions (\> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol. As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer.

Sponsors & Collaborators

  • University of Basel

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Kurt E Hersberger, Prof. · Pharmaceutical Care Research Group

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-11-30
Completion
2016-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02703727 on ClinicalTrials.gov